Dargad Ramesh R, Parekh Jai D, Dargad Rohit R, Kukrety Shweta
Consulting Physician and Cardiologist, Lilavati, Seven Hills and L.H. Hiranandani Hospital.
Medical Graduate, B.J. Medical College, Pune, Maharashtra.
J Assoc Physicians India. 2016 Mar;64(3):96-98.
To describe the efficacy and safety profile of the new angiotensin receptor blocker (ARB), "Azilsartan Medoxomil", reviewing data available from both clinical and pre-clinical studies.
We completed a review of the English literature from PubMed using the keywords- azilsartan medoxomil, angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACEi) and hypertension.
Many clinical trials have been conducted comparing the efficacy of azilsartan with other ARB's and also with the ACEi ramipril. The trials have shown azilsartan to be more effective in reducing the mean 24-hour systolic blood pressure compared to its counterparts.
Azilsartan is a recently approved ARB and appears to be more efficacious in reducing blood pressure (BP) than the other ARBs with a similar safety and tolerability profile. Azilsartan's very high affinity to and slow dissociation from the angiotensin 1 receptor (AT1R) along with its inverse agonistic properties make it a very good candidate for clinical effects beyond simple BP control, potentially counteracting cardiac hypertrophy, cardiac fibrosis and insulin resistance, together with improved reno-protection and atherosclerotic plaque stabilization.
通过回顾临床和临床前研究的现有数据，描述新型血管紧张素受体阻滞剂（ARB）“阿齐沙坦美洛昔酯”的疗效和安全性。
我们使用关键词“阿齐沙坦美洛昔酯”、“血管紧张素受体阻滞剂（ARB）”、“血管紧张素转换酶抑制剂（ACEi）”和“高血压”，完成了对来自PubMed的英文文献的综述。
已经进行了许多临床试验，比较阿齐沙坦与其他ARB以及与ACEi雷米普利的疗效。试验表明，与同类药物相比，阿齐沙坦在降低24小时平均收缩压方面更有效。
阿齐沙坦是最近获批的一种ARB，在降低血压（BP）方面似乎比其他具有相似安全性和耐受性的ARB更有效。阿齐沙坦对血管紧张素1受体（AT1R）具有非常高的亲和力且与之解离缓慢，同时具有反向激动特性，这使其成为除简单控制血压之外还具有临床效果的非常好的候选药物，可能抵消心脏肥大、心脏纤维化和胰岛素抵抗，同时改善肾脏保护作用和稳定动脉粥样硬化斑块。
